# Fiscus Ventures

> Fiscus Ventures is a VC fund backing Biotechnology and Medical. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Apr 2023
- Lead investor: 40%
- Last updated: Aug 2026

Fiscus Ventures is an investment firm

## Contacts

5 contacts available for Fiscus Ventures. Shizune tracks 1 team members at Fiscus Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/fiscus-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Life Science | 2 | 40% |
| Medical Device | 2 | 40% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 60% |
| Series B | 1 | 20% |
| Series E | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ted Koutouzis | Managing Director | 4 | https://shizune.co/investors/profile/ted-koutouzis |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M | Series E | Apr 25, 2023 |  |
| Ansa Biotechnologies | Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerateinnovation in biological research and engineering. | $68M | Series A | Apr 11, 2022 |  |
| Mekonos | Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip. Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development. | $25M | Series A | Nov 09, 2021 |  |
| SomaLogic | SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscantechnology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado. | $121M | Series A | Nov 25, 2020 |  |
| Exo | Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical,real-time decisions that improve patient outcomes.The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible. | $40M | Series B | Aug 20, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [Reimagined Ventures](https://shizune.co/investors/profile/reimagined-ventures) — VC Fund, 4 deals together
- [Peak 6](https://shizune.co/investors/profile/peak6-investments) — VC Fund, 3 deals together
- [TDK Ventures](https://shizune.co/investors/profile/tdk-ventures) — VC Fund, 2 deals together
- [Action Potential Venture Capital](https://shizune.co/investors/profile/action-potential-venture-capital) — VC Fund, 1 deal together
- [Altitude Life Science Ventures](https://shizune.co/investors/profile/altitude-life-science-ventures) — VC Fund, 1 deal together
- [AMR Action Fund](https://shizune.co/investors/profile/amr-action-fund) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Fiscus Ventures invest in?

Fiscus Ventures invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Fiscus Ventures?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Fiscus Ventures?

The team at Fiscus Ventures includes Ted Koutouzis (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co